Looking at the last two appendix 4cs. I can the figures are building up nicely.
Now add dapsone gel line to it we should see the figures are going up significantly.
Cash flow should be positive as of next quarter. Cash reserves looks healthy too, should be $10 to 15 millions by EFY equal to market cap now.
IMC with half of ACR revenue with barely significant products has twice the market cap of ACR.
I m fair to say, ACR will have a lot of positive upside from here once market realises its financial position.
Ann: Launch of Dapsone 5%, Gel in the United States, page-17
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
